Lynda Charters

The main outcomes were the national prevalence of impaired presenting distance VA, presenting near VA, and contrast sensitivity.

The research team retrospectively studied the long-term corneal endothelial cell changes and visual outcomes after this iris-fixated phakic IOL was explanted in patients with endothelial damage and investigated any potential predictors of endothelial injury.

A recent study showed herpesvirus DNA in a high percentage of corneal grafts after transplantation.

New research identifies potential new TED biomarkers based on the disease activity or inactivity.

Though rare, visual decreases can occur within 1 day postoperatively after phacoemulsification surgery.

A multicenter US study revealed that the long-term use of metformin to treat diabetes and lifestyle changes in patients with diabetes were not associated with the risk of age-related macular degeneration (AMD).

Researchers reported that the preclinical detectable phase for OAG is about 10 years.

The glaucoma field is on the move with significant innovations in a number of treatment areas. Experts discussed the various technologies at the Optometry Times 2022 EyeCon meeting in Marco Island, Florida.

Three experts in myopia control convened at the Optometry Times EyeCon meeting to discuss methods to control this burgeoning global epidemic.

Panel discusses the highs and lows of treating patients with this condition.

Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.

The FDA granted orphan drug designation to BRM424 (BRIM Biotechnology) to treat neurotrophic keratitis (NK).

According to the authors, a patient with bilateral choroid metastases from breast cancer experienced "a dramatic response" after a combination treatment of abemaciclib and fulvestrant.

Teplizumab may work by binding to certain immune system cells that attack insulin-producing cells and increase the proportion of cells that help moderate the immune response, thus delaying progression to stage 3 type 1 diabetes.

The main outcome measures were the baseline cataract severity and self-reported cataract surgery at a 15-year visit.

Obesity can affect retinal structures differently.

This research collaboration between Chinese and Australian researchers set out to investigate the connection in the UK Biobank Study cohort.

It was reported that the more individuals smoke, the faster the retinal nerve fiber layer (RNFL) becomes thinner.

Awareness of visual impairment in clinical practice is suboptimal, and adherence to ophthalmologic evaluation needs to be improved. The prospective cohort study in the Netherlands included 170 children aged 0 to 18 years with a newly diagnosed brain tumor.

World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.

Treatment suspension has negative impact on visual function.

Several risk factors beyond intraocular pressure contribute to open-angle glaucoma.

The web-based, self-guided software application is accessed through touchscreen mobile devices.

A recent report shows that 61 drugs were associated with the development of acute angle-closure (AAC) glaucoma.

Potential for treatment strategy to prevent blindness from glaucoma.

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all tertiles.

Spanish investigators recently reported the case of a 42-year-old man with monkeypox presenting with conjunctivitis.

The treatment of vision problems can help improve the quality of life for many people in the city.

Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia

Optometrists are seeing recent advances in topical therapies that entered the market following decades of reliance of traditional single-agent drops. An implantable device that facilitates the slow release of drug is changing the landscape in glaucoma therapy.